1009303-54-1

Basic information

• Product Name: {5-[2-Chloro-4-((R)-3-methyl-morpholin-4-yl)-pyrido[2,3-d]pyrimidin-7-yl]-2-methoxy-phenyl}-methanol
• Synonyms: {5-[2-Chloro-4-((R)-3-methyl-morpholin-4-yl)-pyrido[2,3-d]pyrimidin-7-yl]-2-methoxy-phenyl}-methanol
• CAS NO: 1009303-54-1
• Molecular Weight: 400.865
• Mol File: 1009303-54-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: {5-[2-Chloro-4-((R)-3-methyl-morpholin-4-yl)-pyrido[2,3-d]pyrimidin-7-yl]-2-methoxy-phenyl}-methanol(CAS DataBase Reference)
• NIST Chemistry Reference: {5-[2-Chloro-4-((R)-3-methyl-morpholin-4-yl)-pyrido[2,3-d]pyrimidin-7-yl]-2-methoxy-phenyl}-methanol(1009303-54-1)
• EPA Substance Registry System: {5-[2-Chloro-4-((R)-3-methyl-morpholin-4-yl)-pyrido[2,3-d]pyrimidin-7-yl]-2-methoxy-phenyl}-methanol(1009303-54-1)

Safety Data

• Hazardous Substances Data: 1009303-54-1(Hazardous Substances Data)

Upstream product

• 13780-71-7 dihydroxyborane 
• 14221-01-3 tetrakis(triphenylphosphine) palladium⁽⁰⁾ 
• 1009303-42-7 (S)-4-(2,7-dichloropyrido[2,3-d]pyrimidin-4-yl)-3-methylmorpholine 

Relevant articles and documents

COMBINATION 059

This invention relates to a combination product, as defined herein, comprising a MEK inhibitor and a mTOR-selective inhibitor, and to methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More specifically the present invention relates to; a combination product, as defined herein, comprising a MEK inhibitor and a mTOR-selective inhibitor; a combination product, as defined herein, comprising a kit of parts comprising a MEK inhibitor and a mTOR-selective inhibitor; use of the combination product, as defined herein, in the treatment of cancer; a method of treating cancer comprising administering the combination product, as defined herein, to a patient. The combination product, as defined herein, and methods of the invention are also useful in the treatment of other diseases associated with the activity of MEK, and/or mTOR.